UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
Date of Report (Date of Earliest event Reported): April 14, 2008 (March 31, 2008) |
||||||||
| CHINA BIOLOGIC PRODUCTS, INC. | ||||||||
| (Exact name of registrant as specified in its charter) | ||||||||
| Delaware | 000-52807 | 75-2308816 | ||||||
| (State of Incorporation) | (Commission File No.) | (IRS Employer ID No.) | ||||||
| No. 14 East Hushan Road, | ||||||||
| Taian City, Shandong 271000 | ||||||||
| People’s Republic of China | ||||||||
| (Address of Principal Executive Offices) | ||||||||
| (+86) 538 -620-3897 | ||||||||
| Registrant’s Telephone Number, Including Area Code | ||||||||
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
£
Written communications pursuant to Rule 425 under the Securities Act (17 CFR.425)
£
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION. On March 31, 2008, China Biologic
Products, Inc. (the "Company") issued a press release announcing its financial
results for the fiscal year ended December 31, 2007. A copy of the press release
is furnished as Exhibit 99.1 hereto. In accordance with General
Instruction B.2 of Form 8-K, the information in this Report, including Exhibit
99.1 hereto, shall not be deemed to be "filed" for purposes of Section 18 of the
Exchange Act, or otherwise subject to the liabilities of that section, and shall
not be incorporated by reference into any registration statement or other
document filed under the Securities Act or the Exchange Act, except as shall be
expressly set forth by specific reference in such filing. ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS
(d) Exhibits
| Exhibit No. | Description |
| 99.1 | Press Release dated March 31, 2008 |
SIGNATURES Pursuant to the requirements of the
Securities and Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned hereunto duly authorized.
| CHINA BIOLOGIC PRODUCTS, INC. | ||
| Date: April 14, 2008 | /s/ Stanley Wong | |
| Stanley Wong | ||
| President and Chief Executive Officer | ||
Exhibit Index
| Number | Description |
| 99.1 | Press Release dated March 31, 2008 |